2024
-
Photo Gallery: SABCS® Celebration
Attendees gathered Thursday evening for the inaugural SABCS® Celebration. View photos from the event, which featured live music, dancing, and chances to catch up with colleagues.
-
General Session 2 features practice-changing findings, including late-breaking data from PATINA trial
Otto Metzger, MD; E. Shelley Hwang, MD, MPH; and Ann H. Partridge, MD, MPH, were among 10 experts reporting results Thursday during the second General Session of the 2024 San Antonio Breast Cancer Symposium®.
-
McGuire Lecturer reviews trailblazing work in unlocking the molecular biology of breast cancer
2024 William L. McGuire Memorial Lecture Award recipient Laura J. van ‘t Veer, PhD, reviewed career milestones, including the invention of the 70-gene MammaPrint lab test, during her address on Wednesday.
-
SABCS® Daily Highlights for Friday, December 13
Plan your Friday schedule and don’t miss notable items on the program, including the third General Session, a session for pathologists about IHC testing, and a debate on universal germline genetic testing.
-
Close out the 2024 SABCS® with can’t-miss insights for research, clinical practice
The Year in Review and View from the Trenches sessions on Friday afternoon and evening will wrap up this year’s Symposium and set the stage for discussions to come.
-
SABCS Snippets: Artificial intelligence in the clinic
Emily Ray, MD, MPH, talks with Ian Maurer, MS, about the potential advantages and limitations of using AI in oncology and in the clinic.
-
Investigators to highlight vaccines and other new directions in breast cancer prevention
Olivera (Olja) J. Finn, PhD, will explore the progress and challenges related to therapeutic cancer vaccines during a Friday afternoon session on breast cancer risk reduction and early detection.
-
Experts to debate whether all breast cancer patients should be offered universal germline genetic testing
Allison Kurian, MD, MSc, and Raymond Kim, MD, PhD, will share opposing perspectives on germline testing for genetic variants associated with breast cancer during a Friday afternoon debate.
-
SABCS Snippets: Results of the COMET study (AFT-25)
Taiwo Adesoye, MD, MPH, talks with Eun-Sil Shelley Hwang, MD, about the results of the COMET study, which finds that active monitoring is a viable option for some patients with low-risk DCIS.
-
SABCS Snippets: Results from the AFT-38 PATINA trial
Lisa Anne Carey, MD, talks with Otto Metzger, MD, about the results of the phase 3 PATINA trial, which evaluated the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy after induction treatment for hormone receptor-positive (HR+)/HER-positive metastatic breast cancer.